Literature DB >> 19018234

Paraoxonase-1 55/192 genotypes in schizophrenic patients and their relatives in Turkish population.

Cem Ismail Kucukali1, Makbule Aydin, Elif Ozkok, Nurcan Orhan, Ulku Cakir, Gamze Kilic, Zeynep Ozbek, Nurhan Ince, Ihsan Kara.   

Abstract

BACKGROUND: Oxidative stress and free radical-induced toxicity have been implicated in the pathophysiology of schizophrenia. In this study, we examined paraoxonase (PON1)-55/192 polymorphisms and PON1 activity in patients with schizophrenia, first-degree relatives of schizophrenic patients, and healthy controls.
METHODS: This study consisted of 292 healthy participants, 267 unrelated patients with schizophrenia and 311 first-degree relatives of schizophrenic patients. PON1 55 (rs 854560) and PON1 192 (rs 662) polymorphisms were performed by restriction fragment length polymorphism.
RESULTS: The frequencies of the QQ and LL genotypes were significantly overpresented in controls compared with those of schizophrenic patients and their relatives. In contrast, the RR genotype was more prevalent in patients than their relatives and healthy controls. The frequencies of the LM and QR genotypes in relatives were higher than controls. Serum PON1 activities of controls were significantly higher when compared with both schizophrenic patients and their relatives. The RR and LL genotypes were associated with a significantly increased PON1 activity as compared with QR or QQ and MM or LM genotypes, respectively, in all groups.
CONCLUSION: This is the first study that shows the association between PON1-55/192 polymorphisms and schizophrenia. Our data suggest that the subjects carrying R allele or RR genotype might be susceptible to schizophrenia and subjects with QQ or LL might be protected against schizophrenia. First-degree relatives of schizophrenic patients have higher heterozygote genotypes, suggesting that this group can shift either to patient or control group depending on their allele types and environmental factors. PON1 genetic variations are also associated with PON1 activities. Reduced PON1 activity in patients and their relatives might result from the combined effects of more than one polymorphic variant in PON1 or other genes and/or increased oxidative stress, supporting the hypothesis that reactive oxygen species-mediated cellular damage might contribute to the neuropathology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018234     DOI: 10.1097/YPG.0b013e3283060f94

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  9 in total

Review 1.  Genetic association studies of antioxidant pathway genes and schizophrenia.

Authors:  Kodavali V Chowdari; Mikhil N Bamne; Vishwajit L Nimgaonkar
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

2.  Paraoxonase 1 (PON1) polymorphisms and risk for migraine.

Authors:  Elena García-Martín; Carmen Martínez; Mercedes Serrador; Hortensia Alonso-Navarro; Francisco Navacerrada; José A G Agúndez; Félix Javier Jiménez-Jiménez
Journal:  J Neurol       Date:  2010-04-21       Impact factor: 4.849

3.  Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis.

Authors:  Carmen Martínez; Elena García-Martín; Julián Benito-León; Patricia Calleja; María Díaz-Sánchez; Diana Pisa; Hortensia Alonso-Navarro; Lucía Ayuso-Peralta; Dolores Torrecilla; José A G Agúndez; Félix Javier Jiménez-Jiménez
Journal:  Neuromolecular Med       Date:  2009-10-14       Impact factor: 3.843

4.  PON1 and neurodevelopment in children from the CHAMACOS study exposed to organophosphate pesticides in utero.

Authors:  Brenda Eskenazi; Karen Huen; Amy Marks; Kim G Harley; Asa Bradman; Dana Boyd Barr; Nina Holland
Journal:  Environ Health Perspect       Date:  2010-12       Impact factor: 9.031

5.  Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma.

Authors:  Carmen Martínez; José A Molina; Hortensia Alonso-Navarro; Félix J Jiménez-Jiménez; José A G Agúndez; Elena García-Martín
Journal:  BMC Neurol       Date:  2010-08-19       Impact factor: 2.474

6.  The determination of Q192R polymorphism of paraoxonase 1 by using non-toxic substrate p-nitrophenylacetate.

Authors:  M R Mogarekar; Seema S Chawhan
Journal:  Indian J Hum Genet       Date:  2013-01

7.  Genotype-phenotype Analysis of Paraoxonase 1 in Schizophrenic Patients Treated with Atypical Antipsychotics.

Authors:  Denis Pavăl; Bogdan Nemeș; Răzvan L Rusu; Eleonora Dronca
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-02-28       Impact factor: 2.582

Review 8.  Multifactorial Origin of Neurodevelopmental Disorders: Approaches to Understanding Complex Etiologies.

Authors:  Alessia De Felice; Laura Ricceri; Aldina Venerosi; Flavia Chiarotti; Gemma Calamandrei
Journal:  Toxics       Date:  2015-03-23

Review 9.  Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?

Authors:  Estefania Gastaldello Moreira; Karine Maria Boll; Dalmo Guilherme Correia; Janaina Favaro Soares; Camila Rigobello; Michael Maes
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.